Joseph G Ibrahim

List of Publications by Year in Descending Order

289 papers	12,539 citations	53 h-index	104 g-index
297 ext. papers	14,196 ext. citations	2.7 avg, IF	6.35 L-index

#	Paper	IF	Citations
289	Large-scale GWAS reveals genetic architecture of brain white matter microstructure and genetic overlap with cognitive and mental health traits (n = 17,706). *Molecular Psychiatry*, **2021**, 26, 3943-3955	15.1	35
288	MODEL-BASED FEATURE SELECTION AND CLUSTERING OF RNA-SEQ DATA FOR UNSUPERVISED SUBTYPE DISCOVERY. *Annals of Applied Statistics*, **2021**, 15, 481-508	2.1	1
287	MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of allelic heterogeneity. *PLoS Genetics*, **2021**, 17, e1009455	6	4
286	Inferring latent heterogeneity using many feature variables supervised by survival outcome. *Statistics in Medicine*, **2021**, 40, 3181-3195	2.3	
285	Bayesian network meta-regression hierarchical models using heavy-tailed multivariate random effects with covariate-dependent variances. *Statistics in Medicine*, **2021**, 40, 3582-3603	2.3	
284	Weighted functional linear Cox regression model. *Statistical Methods in Medical Research*, **2021**, 30, 1917-1931	2.3	2
283	On the normalized power prior. *Statistics in Medicine*, **2021**, 40, 5251-5275	2.3	2
282	Bayesian adaptive basket trial design using model averaging. *Biostatistics*, **2021**, 22, 19-34	3.7	8
281	Joint modelling of longitudinal and survival data in the presence of competing risks with applications to prostate cancer data. *Statistical Modelling*, **2021**, 21, 72-94	0.7	1
280	Network meta-regression for ordinal outcomes: Applications in comparing Crohn₃ disease treatments. *Statistics in Medicine*, **2020**, 39, 1846	2.3	1
279	Partial least squares for functional joint models with applications to the Alzheimer₃ disease neuroimaging initiative study. *Biometrics*, **2020**, 76, 1109-1119	1.8	2
278	A hierarchical testing approach for detecting safety signals in clinical trials. *Statistics in Medicine*, **2020**, 39, 1541-1557	2.3	3
277	Penalized logistic regression using functional connectivity as covariates with an application to mild cognitive impairment. *Communications for Statistical Applications and Methods*, **2020**, 27, 603-624	0.4	
276	Bayesian flexible hierarchical skew heavy-tailed multivariate meta regression models for individual patient data with applications. *Statistics and Its Interface*, **2020**, 13, 485-500	0.4	0
275	Bayesian design of biosimilars clinical programs involving multiple therapeutic indications. *Biometrics*, **2020**, 76, 630-642	1.8	1
274	Global identifiability of latent class models with applications to diagnostic test accuracy studies: A Gr₃bner basis approach. *Biometrics*, **2020**, 76, 98-108	1.8	1
273	Modeling Between-Study Heterogeneity for Improved Replicability in Gene Signature Selection and Clinical Prediction. *Journal of the American Statistical Association*, **2020**, 115, 1125-1138	2.8	5

272	Joint analysis of single-cell and bulk tissue sequencing data to infer intratumor heterogeneity. *Biometrics*, **2020**, 76, 983-994	1.8	1
271	Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data With Informative Censoring. *Statistics in Biopharmaceutical Research*, **2020**, 1-9	1.2	1
270	A marginal estimate for the overall treatment effect on a survival outcome within the joint modeling framework. *Statistics in Medicine*, **2020**, 39, 4120-4132	2.3	1
269	ICeD-T Provides Accurate Estimates of Immune Cell Abundance in Tumor Samples by Allowing for Aberrant Gene Expression Patterns. *Journal of the American Statistical Association*, **2020**, 115, 1055-1065	2.8	4
268	Semiparametric frailty models for zero-inflated event count data in the presence of informative dropout. *Biometrics*, **2019**, 75, 1168-1178	1.8	2
267	Quantifying time-varying cause-specific hazard and subdistribution hazard ratios with competing risks data. *Clinical Trials*, **2019**, 16, 363-374	2.2	1
266	Improved detection of epigenomic marks with mixed-effects hidden Markov models. *Biometrics*, **2019**, 75, 1401-1413	1.8	
265	Efficient methods for signal detection from correlated adverse events in clinical trials. *Biometrics*, **2019**, 75, 1000-1008	1.8	2
264	Nonparametric expression analysis using inferential replicate counts. *Nucleic Acids Research*, **2019**, 47, e105	20.1	14
263	Controlling false discovery proportion in identification of drug-related adverse events from multiple system organ classes. *Statistics in Medicine*, **2019**, 38, 4378-4389	2.3	2
262	A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials. *Statistics in Medicine*, **2019**, 38, 5565-5586	2.3	2
261	A Powerful Global Test Statistic for Functional Statistical Inference. *Proceedings of the AAAI Conference on Artificial Intelligence*, **2019**, 33, 5765-5772	5	
260	Bayesian multivariate skew meta-regression models for individual patient data. *Statistical Methods in Medical Research*, **2019**, 28, 3415-3436	2.3	1
259	Hard thresholding regression. *Scandinavian Journal of Statistics*, **2019**, 46, 314-328	0.8	4
258	Bayesian clinical trial design using historical data that inform the treatment effect. *Biostatistics*, **2019**, 20, 400-415	3.7	29
257	Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugs. *Biostatistics*, **2019**, 20, 499-516	3.7	2
256	MILFM: Multiple index latent factor model based on high-dimensional features. *Biometrics*, **2018**, 74, 834-844	1.8	4
255	A Bayesian hierarchical model for network meta-analysis of multiple diagnostic tests. *Biostatistics*, **2018**, 19, 87-102	3.7	11

254	Biomarker threshold adaptive designs for survival endpoints. *Journal of Biopharmaceutical Statistics*, **2018**, 28, 1038-1054	1.3	4
253	Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials. *Journal of Allergy and Clinical Immunology*, **2018**, 141, 1744-1749	11.5	9
252	FLCRM: Functional linear cox regression model. *Biometrics*, **2018**, 74, 109-117	1.8	25
251	A practical Bayesian adaptive design incorporating data from historical controls. *Statistics in Medicine*, **2018**, 37, 4054-4070	2.3	11
250	Bayesian design of a survival trial with a cured fraction using historical data. *Statistics in Medicine*, **2018**, 37, 3814-3831	2.3	2
249	Semiparametric regression analysis for composite endpoints subject to componentwise censoring. *Biometrika*, **2018**, 105, 403-418	2	2
248	Bayesian Modeling and Inference for Nonignorably Missing Longitudinal Binary Response Data with Applications to HIV Prevention Trials. *Statistica Sinica*, **2018**, 28, 1929-1963	0.7	3
247	Functional Linear Regression Models for Nonignorable Missing Scalar Responses. *Statistica Sinica*, **2018**, 28, 1867-1886	0.7	1
246	Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study. *Statistics in Biosciences*, **2018**, 10, 473-489	1.5	0
245	The effects of nonignorable missing data on label-free mass spectrometry proteomics experiments. *Annals of Applied Statistics*, **2018**, 12, 2075-2095	2.1	22
244	TPRM: TENSOR PARTITION REGRESSION MODELS WITH APPLICATIONS IN IMAGING BIOMARKER DETECTION. *Annals of Applied Statistics*, **2018**, 12, 1422-1450	2.1	8
243	Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data with Applications to Cancer Clinical Trials. *Journal of Computational and Graphical Statistics*, **2017**, 26, 121-133	1.4	17
242	Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects. *Journal of Biopharmaceutical Statistics*, **2017**, 27, 933-944	1.3	3
241	Bayesian longitudinal low-rank regression models for imaging genetic data from longitudinal studies. *NeuroImage*, **2017**, 149, 305-322	7.9	10
240	On inference of control-based imputation for analysis of repeated binary outcomes with missing data. *Journal of Biopharmaceutical Statistics*, **2017**, 27, 358-372	1.3	8
239	Pattern mixture models for clinical validation of biomarkers in the presence of missing data. *Statistics in Medicine*, **2017**, 36, 2994-3004	2.3	
238	Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome. *Statistics in Medicine*, **2017**, 36, 3475-3494	2.3	3
237	Bayesian clinical trial design using Markov models with applications to autoimmune disease. *Contemporary Clinical Trials*, **2017**, 63, 73-83	2.3	0

236	Bayesian Sensitivity Analysis of a Nonlinear Dynamic Factor Analysis Model with Nonparametric Prior and Possible Nonignorable Missingness. *Psychometrika*, **2017**, 82, 875-903	2.2	8
235	Control-based imputation for sensitivity analyses in informative censoring for recurrent event data. *Pharmaceutical Statistics*, **2017**, 16, 424-432	1	8
234	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. *Lancet Oncology, The*, **2017**, 18, 132-142	21.7	90
233	LCN: a random graph mixture model for community detection in functional brain networks. *Statistics and Its Interface*, **2017**, 10, 369-378	0.4	4
232	SR-HARDI: Spatially Regularizing High Angular Resolution Diffusion Imaging. *Journal of Computational and Graphical Statistics*, **2016**, 25, 1195-1211	1.4	
231	JMFit: A SAS Macro for Joint Models of Longitudinal and Survival Data. *Journal of Statistical Software*, **2016**, 71,	7.3	30
230	Reply to Comments. *Statistics in Medicine*, **2016**, 35, 1560	2.3	
229	A STATISTICAL MODEL TO ASSESS (ALLELE-SPECIFIC) ASSOCIATIONS BETWEEN GENE EXPRESSION AND EPIGENETIC FEATURES USING SEQUENCING DATA. *Annals of Applied Statistics*, **2016**, 10, 2254-2273	2.1	2
228	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. *Oncologist*, **2016**, 21, 795-803	5.7	28
227	The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies. *Journal of Biopharmaceutical Statistics*, **2015**, 25, 66-88	1.3	7
226	A counterfactual p-value approach for benefit-risk assessment in clinical trials. *Journal of Biopharmaceutical Statistics*, **2015**, 25, 508-24	1.3	1
225	SPReM: Sparse Projection Regression Model For High-dimensional Linear Regression. *Journal of the American Statistical Association*, **2015**, 110, 289-302	2.8	8
224	Quantifying the average of the time-varying hazard ratio via a class of transformations. *Lifetime Data Analysis*, **2015**, 21, 259-79	1.3	4
223	Assessment of Fit in Longitudinal Data for Joint Models with Applications to Cancer Clinical Trials. *ICSA Book Series in Statistics*, **2015**, 347-365	0.3	2
222	DNA damage checkpoint responses in the S phase of synchronized diploid human fibroblasts. *Photochemistry and Photobiology*, **2015**, 91, 109-16	3.6	8
221	Bayesian Inference for Multivariate Meta-regression with a Partially Observed Within-Study Sample Covariance Matrix. *Journal of the American Statistical Association*, **2015**, 110, 528-544	2.8	7
220	Homology cluster differential expression analysis for interspecies mRNA-Seq experiments. *Statistical Applications in Genetics and Molecular Biology*, **2015**, 14, 507-16	1.2	1
219	Diagnostic Measures for the Cox Regression Model with Missing Covariates. *Biometrika*, **2015**, 102, 907-923	2	8

218	Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. *Statistics in Medicine*, **2015**, 34, 2181-95	2.3	79
217	Bayesian probability of success for clinical trials using historical data. *Statistics in Medicine*, **2015**, 34, 249-64	2.3	11
216	BFLCRM: A BAYESIAN FUNCTIONAL LINEAR COX REGRESSION MODEL FOR PREDICTING TIME TO CONVERSION TO ALZHEIMER'S DISEASE. *Annals of Applied Statistics*, **2015**, 9, 2153-2178	2.1	19
215	In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles. *British Journal of Clinical Pharmacology*, **2015**, 80, 1122-30	3.8	30
214	Hypothesis testing for two-stage designs with over or under enrollment. *Statistics in Medicine*, **2015**, 34, 2417-26	2.3	5
213	The power prior: theory and applications. *Statistics in Medicine*, **2015**, 34, 3724-49	2.3	102
212	Assessing temporal agreement between central and local progression-free survival times. *Statistics in Medicine*, **2015**, 34, 844-58	2.3	1
211	Responses to discussants of ?Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group?. *Statistics in Medicine*, **2015**, 34, 2202-3	2.3	5
210	Mechanisms of chromosomal instability in melanoma. *Environmental and Molecular Mutagenesis*, **2014**, 55, 457-71	3.2	9
209	Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials. *Statistics in Medicine*, **2014**, 33, 4715-33	2.3	27
208	Bayesian Generalized Low Rank Regression Models for Neuroimaging Phenotypes and Genetic Markers. *Journal of the American Statistical Association*, **2014**, 109, 977-990	2.8	43
207	Bayesian Transformation Models for Multivariate Survival Data. *Scandinavian Journal of Statistics*, **2014**, 41, 187-199	0.8	0
206	Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program. *Statistics in Medicine*, **2014**, 33, 1600-18	2.3	12
205	A community-based multicenter trial of pharmacokinetically guided 5-fluorouracil dosing for personalized colorectal cancer therapy. *Oncologist*, **2014**, 19, 959-65	5.7	31
204	Multivariate recurrent events in the presence of multivariate informative censoring with applications to bleeding and transfusion events in myelodysplastic syndrome. *Journal of Biopharmaceutical Statistics*, **2014**, 24, 429-42	1.3	8
203	Cyclobutane Pyrimidine Dimer Density as a Predictive Biomarker of the Biological Effects of Ultraviolet Radiation in Normal Human Fibroblast. *Photochemistry and Photobiology*, **2014**, 90, 145-54	3.6	6
202	Post-diagnosis physical activity and survival after breast cancer diagnosis: the Long Island Breast Cancer Study. *Breast Cancer Research and Treatment*, **2014**, 145, 735-42	4.4	45
201	Some Statistical Strategies for DAE-seq Data Analysis: Variable Selection and Modeling Dependencies among Observations. *Journal of the American Statistical Association*, **2014**, 109, 78-94	2.8	5

#	Reference		
200	Bayesian Survival Analysis **2014**,		9
199	Functional-mixed effects models for candidate genetic mapping in imaging genetic studies. *Genetic Epidemiology*, **2014**, 38, 680-91	2.6	6
198	Sample size determination in shared frailty models for multivariate time-to-event data. *Journal of Biopharmaceutical Statistics*, **2014**, 24, 908-23	1.3	3
197	Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. *Journal of Biopharmaceutical Statistics*, **2014**, 24, 817-33	1.3	8
196	Use of historical control data for assessing treatment effects in clinical trials. *Pharmaceutical Statistics*, **2014**, 13, 41-54	1	218
195	Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates. *Statistics in Medicine*, **2014**, 33, 4560-76	2.3	22
194	Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. *Journal of the National Cancer Institute*, **2014**, 106, dju057	9.7	157
193	Development of DNA damage response signaling biomarkers using automated, quantitative image analysis. *Journal of Histochemistry and Cytochemistry*, **2014**, 62, 185-96	3.4	13
192	Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodyplastic syndrome. *Biometrics*, **2014**, 70, 1003-13	1.8	10
191	Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching. *Lifetime Data Analysis*, **2014**, 20, 76-105	1.3	14
190	A note on the relationships between multiple imputation, maximum likelihood and fully Bayesian methods for missing responses in linear regression models. *Statistics and Its Interface*, **2014**, 6, 315-324	0.4	6
189	Bayesian Case-deletion Model Complexity and Information Criterion. *Statistics and Its Interface*, **2014**, 7, 531-542	0.4	2
188	Bayesian Sensitivity Analysis of Statistical Models with Missing Data. *Statistica Sinica*, **2014**, 24, 871-896	0.7	7
187	Change-point models to estimate the limit of detection. *Statistics in Medicine*, **2013**, 32, 4995-5007	2.3	4
186	Pathologic and gene expression features of metastatic melanomas to the brain. *Cancer*, **2013**, 119, 2737-46	6.2	39
185	Estimating time-varying effects for overdispersed recurrent events data with treatment switching. *Biometrika*, **2013**, 100, 339-354	2	9
184	Separation of intra-S checkpoint protein contributions to DNA replication fork protection and genomic stability in normal human fibroblasts. *Cell Cycle*, **2013**, 12, 332-45	4.7	15
183	Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs. *Statistics in Medicine*, **2013**, 32, 3972-90	2.3	8

182	Bayesian modeling and inference for clinical trials with partial retrieved data following dropout. *Statistics in Medicine*, **2013**, 32, 4180-95	2.3	3
181	Bayesian spatial transformation models with applications in neuroimaging data. *Biometrics*, **2013**, 69, 1074-83	1.8	6
180	A prognostic signature of G(2) checkpoint function in melanoma cell lines. *Cell Cycle*, **2013**, 12, 1071-82	4.7	10
179	Is activation of the intra-S checkpoint in human fibroblasts an important factor in protection against UV-induced mutagenesis?. *Cell Cycle*, **2013**, 12, 3555-63	4.7	3
178	Mapping the genetic variation of regional brain volumes as explained by all common SNPs from the ADNI study. *PLoS ONE*, **2013**, 8, e71723	3.7	20
177	The Bayesian Covariance Lasso. *Statistics and Its Interface*, **2013**, 6, 243-259	0.4	25
176	Bayesian meta-experimental design: evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. *Biometrics*, **2012**, 68, 578-86	1.8	27
175	Bayesian influence measures for joint models for longitudinal and survival data. *Biometrics*, **2012**, 68, 954-64	1.8	21
174	Bayesian lasso for semiparametric structural equation models. *Biometrics*, **2012**, 68, 567-77	1.8	30
173	Intrinsic Regression Models for Medial Representation of Subcortical Structures. *Journal of the American Statistical Association*, **2012**, 107, 12-23	2.8	4
172	Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690. *BMC Medical Research Methodology*, **2012**, 12, 183	4.7	9
171	Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs. *Statistics in Medicine*, **2012**, 31, 3597-616	2.3	3
170	Projection regression models for multivariate imaging phenotype. *Genetic Epidemiology*, **2012**, 36, 631-41	1.6	14
169	Bayesian Case Influence Measures for Statistical Models with Missing Data. *Journal of Computational and Graphical Statistics*, **2012**, 21, 253-271	1.4	9
168	PERTURBATION AND SCALED COOK'S DISTANCE. *Annals of Statistics*, **2012**, 40, 785-811	3.2	17
167	Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development. *Statistics in Biopharmaceutical Research*, **2012**, 4, 293-300	1.2	1
166	Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. *Biometrika*, **2012**, 99, 167-184	2	22
165	Missing data in clinical studies: issues and methods. *Journal of Clinical Oncology*, **2012**, 30, 3297-303	2.2	100

164	Timeless functions independently of the Tim-Tipin complex to promote sister chromatid cohesion in normal human fibroblasts. *Cell Cycle*, **2011**, 10, 1618-24	4.7	23
163	TWO-STAGE EMPIRICAL LIKELIHOOD FOR LONGITUDINAL NEUROIMAGING DATA. *Annals of Applied Statistics*, **2011**, 5, 1132-1158	2.1	6
162	A generalized linear mixed model for longitudinal binary data with a marginal logit link function. *Annals of Applied Statistics*, **2011**, 5, 449-467	2.1	30
161	Fixed and random effects selection in mixed effects models. *Biometrics*, **2011**, 67, 495-503	1.8	74
160	A bivariate pseudolikelihood for incomplete longitudinal binary data with nonignorable nonmonotone missingness. *Biometrics*, **2011**, 67, 1119-26	1.8	3
159	Bayesian design of noninferiority trials for medical devices using historical data. *Biometrics*, **2011**, 67, 1163-70	1.8	44
158	Bayesian local influence for survival models. *Lifetime Data Analysis*, **2011**, 17, 43-70	1.3	9
157	Rejoinder: Bayesian local influence for survival models. *Lifetime Data Analysis*, **2011**, 17, 76-79	1.3	
156	Sample size and power determination in joint modeling of longitudinal and survival data. *Statistics in Medicine*, **2011**, 30, 2295-309	2.3	32
155	Maximum likelihood estimation in generalized linear models with multiple covariates subject to detection limits. *Statistics in Medicine*, **2011**, 30, 2551-61	2.3	26
154	Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. *Journal of Clinical Oncology*, **2011**, 29, 3232-9	2.2	157
153	Bayesian influence analysis: a geometric approach. *Biometrika*, **2011**, 98, 307-323	2	33
152	Variable selection in the cox regression model with covariates missing at random. *Biometrics*, **2010**, 66, 97-104	1.8	15
151	Basic concepts and methods for joint models of longitudinal and survival data. *Journal of Clinical Oncology*, **2010**, 28, 2796-801	2.2	217
150	Genomewide multiple-loci mapping in experimental crosses by iterative adaptive penalized regression. *Genetics*, **2010**, 185, 349-59	4	56
149	Abasic sites preferentially form at regions undergoing DNA replication. *FASEB Journal*, **2010**, 24, 3674-80	0.9	35
148	In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. *Drug Metabolism and Disposition*, **2010**, 38, 25-31	4	98
147	A semiparametric Bayesian approach for estimating the gene expression distribution. *Journal of Biopharmaceutical Statistics*, **2010**, 20, 267-80	1.3	2

146	trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II. *Cancer Causes and Control*, **2010**, 21, 171-80	2.8	28
145	On the estimation of disease prevalence by latent class models for screening studies using two screening tests with categorical disease status verified in test positives only. *Statistics in Medicine*, **2010**, 29, 1206-18	2.3	10
144	A weighted combination of pseudo-likelihood estimators for longitudinal binary data subject to non-ignorable non-monotone missingness. *Statistics in Medicine*, **2010**, 29, 1511-21	2.3	5
143	A Bayesian proportional hazards regression model with non-ignorably missing time-varying covariates. *Statistics in Medicine*, **2010**, 29, 3017-29	2.3	8
142	VARIABLE SELECTION FOR REGRESSION MODELS WITH MISSING DATA. *Statistica Sinica*, **2010**, 20, 149-165	1.7	28
141	INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. *PLoS ONE*, **2009**, 4, e5027	3.7	196
140	Associations between trans fatty acid consumption and colon cancer among Whites and African Americans in the North Carolina colon cancer study I. *Nutrition and Cancer*, **2009**, 61, 427-36	2.8	11
139	Estimation and inference for case-control studies with multiple non-gold standard exposure assessments: with an occupational health application. *Biostatistics*, **2009**, 10, 591-602	3.7	11
138	Gamma frailty transformation models for multivariate survival times. *Biometrika*, **2009**, 96, 277-291	2	25
137	Comment: Incomplete Data in Clinical Studies: Analysis, Sensitivity, and Sensitivity Analysis. *Drug Information Journal*, **2009**, 43, 431-432		2
136	In silico construction of a protein interaction landscape for nucleotide excision repair. *Cell Biochemistry and Biophysics*, **2009**, 53, 101-14	3.2	0
135	Missing data methods in longitudinal studies: a review. *Test*, **2009**, 18, 1-43	1.1	228
134	Rejoinder on: Missing data methods in longitudinal studies: a review. *Test*, **2009**, 18, 68-75	1.1	9
133	Bayesian case influence diagnostics for survival models. *Biometrics*, **2009**, 65, 116-24	1.8	38
132	Local influence for generalized linear models with missing covariates. *Biometrics*, **2009**, 65, 1164-74	1.8	20
131	A Bayesian hidden Markov model for motif discovery through joint modeling of genomic sequence and ChIP-chip data. *Biometrics*, **2009**, 65, 1087-95	1.8	9
130	Diagnostic Measures for Generalized Linear Models with Missing Covariates. *Scandinavian Journal of Statistics*, **2009**, 36, 686-712	0.8	13
129	Expression of p16(INK4a) in peripheral blood T-cells is a biomarker of human aging. *Aging Cell*, **2009**, 8, 439-48	9.9	285

128	Maximum Likelihood Inference for the Cox Regression Model with Applications to Missing Covariates. *Journal of Multivariate Analysis*, **2009**, 100, 2018-2030	1.4	19
127	Regression Models for Identifying Noise Sources in Magnetic Resonance Images. *Journal of the American Statistical Association*, **2009**, 104, 623-637	2.8	36
126	Intrinsic Regression Models for Positive-Definite Matrices With Applications to Diffusion Tensor Imaging. *Journal of the American Statistical Association*, **2009**, 104, 1203-1212	2.8	39
125	An Information Matrix Prior for Bayesian Analysis in Generalized Linear Models with High Dimensional Data. *Statistica Sinica*, **2009**, 19, 1641-1663	0.7	10
124	Defective cell cycle checkpoint functions in melanoma are associated with altered patterns of gene expression. *Journal of Investigative Dermatology*, **2008**, 128, 175-87	4.3	47
123	Model Selection Criteria for Missing-Data Problems Using the EM Algorithm. *Journal of the American Statistical Association*, **2008**, 103, 1648-1658	2.8	77
122	A note on the validity of statistical bootstrapping for estimating the uncertainty of tensor parameters in diffusion tensor images. *IEEE Transactions on Medical Imaging*, **2008**, 27, 1506-14	11.7	9
121	Consumption of trans-fatty acid and its association with colorectal adenomas. *American Journal of Epidemiology*, **2008**, 168, 289-97	3.8	28
120	Current Methods for Recurrent Events Data with Dependent Termination: A Bayesian Perspective. *Journal of the American Statistical Association*, **2008**, 103, 866-878	2.8	21
119	Properties and Implementation of Jeffreys's Prior in Binomial Regression Models. *Journal of the American Statistical Association*, **2008**, 103, 1659-1664	2.8	27
118	n-3 Fatty acids, hypertension and risk of cognitive decline among older adults in the Atherosclerosis Risk in Communities (ARIC) study. *Public Health Nutrition*, **2008**, 11, 17-29	3.3	43
117	Bayesian Variable Selection and Computation for Generalized Linear Models with Conjugate Priors. *Bayesian Analysis*, **2008**, 3, 585-614	2.3	27
116	Bayesian variable selection for the Cox regression model with missing covariates. *Lifetime Data Analysis*, **2008**, 14, 496-520	1.3	9
115	A new class of mixture models for differential gene expression in DNA microarray data. *Journal of Statistical Planning and Inference*, **2008**, 138, 387-404	0.8	5
114	Theory and Inference for Regression Models with Missing Responses and Covariates. *Journal of Multivariate Analysis*, **2008**, 99, 1302-1331	1.4	30
113	Variable Selection in Regression Mixture Modeling for the Discovery of Gene Regulatory Networks. *Journal of the American Statistical Association*, **2007**, 102, 867-880	2.8	32
112	Sieve Maximum Likelihood Estimation for Regression Models With Covariates Missing at Random. *Journal of the American Statistical Association*, **2007**, 102, 1309-1317	2.8	8
111	Perturbation selection and influence measures in local influence analysis. *Annals of Statistics*, **2007**, 35,	3.2	72

110	Bayesian hierarchical modeling for time course microarray experiments. *Biometrics*, **2007**, 63, 496-504	1.8	4
109	A note on permutation tests for variance components in multilevel generalized linear mixed models. *Biometrics*, **2007**, 63, 942-6	1.8	40
108	Proximity model for expression quantitative trait loci (eQTL) detection. *Biometrics*, **2007**, 63, 1108-16	1.8	14
107	Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression. *Toxicology and Applied Pharmacology*, **2007**, 225, 267-77	4.6	18
106	UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. *Journal of the National Cancer Institute*, **2007**, 99, 1290-5	9.7	373
105	A temporal hidden Markov regression model for the analysis of gene regulatory networks. *Biostatistics*, **2007**, 8, 805-20	3.7	9
104	Statistical Analysis of Diffusion Tensors in Diffusion-Weighted Magnetic Resonance Imaging Data. *Journal of the American Statistical Association*, **2007**, 102, 1085-1102	2.8	49
103	Structured measurement error in nutritional epidemiology: applications in the Pregnancy, Infection, and Nutrition (PIN) Study. *Journal of the American Statistical Association*, **2007**, 102, 856-866	2.8	37
102	A statistical analysis of brain morphology using wild bootstrapping. *IEEE Transactions on Medical Imaging*, **2007**, 26, 954-66	11.7	28
101	Posterior propriety and computation for the Cox regression model with applications to missing covariates. *Biometrika*, **2006**, 93, 791-807	2	22
100	Bayesian Model Averaging With Applications to Benchmark Dose Estimation for Arsenic in Drinking Water. *Journal of the American Statistical Association*, **2006**, 101, 9-17	2.8	56
99	Use of the Probability Integral Transformation to Fit Nonlinear Mixed-Effects Models With Nonnormal Random Effects. *Journal of Computational and Graphical Statistics*, **2006**, 15, 39-57	1.4	47
98	Semiparametric Transformation Models for Survival Data With a Cure Fraction. *Journal of the American Statistical Association*, **2006**, 101, 670-684	2.8	88
97	The relationship between the power prior and hierarchical models. *Bayesian Analysis*, **2006**, 1, 551	2.3	54
96	Pseudo-likelihood methods for longitudinal binary data with non-ignorable missing responses and covariates. *Statistics in Medicine*, **2006**, 25, 2784-96	2.3	19
95	Semiparametric models for missing covariate and response data in regression models. *Biometrics*, **2006**, 62, 177-84	1.8	29
94	Joint models for multivariate longitudinal and multivariate survival data. *Biometrics*, **2006**, 62, 432-45	1.8	96
93	Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. *Biostatistics*, **2006**, 7, 469-85	3.7	15

92	Inference for a Class of Transformed Hazards Models. *Journal of the American Statistical Association* , **2005**, 100, 1000-1008	2.8	13
91	Missing-Data Methods for Generalized Linear Models. *Journal of the American Statistical Association* , **2005**, 100, 332-346	2.8	297
90	Bayesian error-in-variable survival model for the analysis of GeneChip arrays. *Biometrics*, **2005**, 61, 488-97	1.8	12
89	A general class of Bayesian survival models with zero and nonzero cure fractions. *Biometrics*, **2005**, 61, 403-12	1.8	21
88	Bayesian analysis for generalized linear models with nonignorably missing covariates. *Biometrics*, **2005**, 61, 767-80	1.8	31
87	A semiparametric mixture model for analyzing clustered competing risks data. *Biometrics*, **2005**, 61, 729-37	1.8	15
86	A class of Bayesian shared gamma frailty models with multivariate failure time data. *Biometrics*, **2005**, 61, 208-16	1.8	19
85	A flexible B-spline model for multiple longitudinal biomarkers and survival. *Biometrics*, **2005**, 61, 64-73	1.8	116
84	Wavelet thresholding with bayesian false discovery rate control. *Biometrics*, **2005**, 61, 25-35	1.8	13
83	Cure rate models: A unified approach. *Canadian Journal of Statistics*, **2005**, 33, 559-570	0.4	101
82	REC, Drosophila MCM8, drives formation of meiotic crossovers. *PLoS Genetics*, **2005**, 1, e40	6	76
81	Bayesian Survival Analysis **2005**,		63
80	A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. *Clinical Cancer Research*, **2004**, 10, 1670-7	12.9	436
79	Propriety of the Posterior Distribution and Existence of the MLE for Regression Models With Covariates Missing at Random. *Journal of the American Statistical Association*, **2004**, 99, 421-438	2.8	18
78	Protective estimator for linear regression with nonignorably missing Gaussian outcomes. *Statistical Modelling*, **2004**, 4, 3-17	0.7	5
77	A bayesian hierarchical model for the analysis of Affymetrix arrays. *Annals of the New York Academy of Sciences*, **2004**, 1020, 41-8	6.5	4
76	A new joint model for longitudinal and survival data with a cure fraction. *Journal of Multivariate Analysis*, **2004**, 91, 18-34	1.4	34
75	Non-ignorable missing covariate data in survival analysis: a case-study of an International Breast Cancer Study Group trial. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2004**, 53, 293-310	1.5	21

74	On Optimality Properties of the Power Prior. *Journal of the American Statistical Association*, **2003**, 98, 204-213	2.8	54
73	Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686). *Melanoma Research*, **2003**, 13, 619-26	3.3	30
72	Prior elicitation for model selection and estimation in generalized linear mixed models. *Journal of Statistical Planning and Inference*, **2003**, 111, 57-76	0.8	30
71	A Bayesian semiparametric joint hierarchical model for longitudinal and survival data. *Biometrics*, **2003**, 59, 221-8	1.8	126
70	Identification of differentially expressed genes in high-density oligonucleotide arrays accounting for the quantification limits of the technology. *Biometrics*, **2003**, 59, 542-54	1.8	12
69	Bayesian approaches to joint cure-rate and longitudinal models with applications to cancer vaccine trials. *Biometrics*, **2003**, 59, 686-93	1.8	64
68	Maximum likelihood methods for nonignorable missing responses and covariates in random effects models. *Biometrics*, **2003**, 59, 1140-50	1.8	51
67	An Estimate of the Odds Ratio That Always Exists. *Journal of Computational and Graphical Statistics*, **2002**, 11, 420-436	1.4	40
66	Bayesian Inference for Multivariate Survival Data with a Cure Fraction. *Journal of Multivariate Analysis*, **2002**, 80, 101-126	1.4	60
65	Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. *Cancer*, **2002**, 95, 1101-12	6.4	75
64	A weighted estimating equation for linear regression with missing covariate data. *Statistics in Medicine*, **2002**, 21, 2421-36	2.3	13
63	Frailty models with missing covariates. *Biometrics*, **2002**, 58, 98-109	1.8	10
62	Parameter estimation in longitudinal studies with outcome-dependent follow-up. *Biometrics*, **2002**, 58, 621-30	1.8	64
61	Bayesian methods for a three-state model for rodent carcinogenicity studies. *Biometrics*, **2002**, 58, 906-16	1.8	12
60	Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group trial E1690. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2002**, 51, 135-150	1.5	16
59	Bayesian methods for missing covariates in cure rate models. *Lifetime Data Analysis*, **2002**, 8, 117-46	1.3	20
58	Use and abuse of statistics in evidence-based medicine. *Journal of Clinical Oncology*, **2002**, 20, 4122-3; author reply 4123-4	2.2	2
57	Maximum likelihood estimation in random effects cure rate models with nonignorable missing covariates. *Biostatistics*, **2002**, 3, 387-405	3.7	12

56	Bayesian methods for generalized linear models with covariates missing at random. *Canadian Journal of Statistics*, **2002**, 30, 55-78	0.4	73
55	Bayesian Models for Gene Expression With DNA Microarray Data. *Journal of the American Statistical Association*, **2002**, 97, 88-99	2.8	113
54	Interferon alfa-2a for melanoma metastases. *Lancet, The*, **2002**, 359, 978-9	40	26
53	Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. *Biology of Blood and Marrow Transplantation*, **2002**, 8, 326-33	4.7	1
52	Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. *Statistics in Medicine*, **2001**, 20, 867-82	2.3	35
51	Bias in estimating association parameters for longitudinal binary responses with drop-outs. *Biometrics*, **2001**, 57, 15-21	1.8	19
50	Maximum likelihood methods for cure rate models with missing covariates. *Biometrics*, **2001**, 57, 43-52	1.8	68
49	Bayesian semiparametric models for survival data with a cure fraction. *Biometrics*, **2001**, 57, 383-8	1.8	67
48	Using auxiliary data for parameter estimation with non-ignorably missing outcomes. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2001**, 50, 361-373	1.5	35
47	Incomplete covariates in the Cox model with applications to biological marker data. *Journal of the Royal Statistical Society Series C: Applied Statistics*, **2001**, 50, 467-484	1.5	5
46	Likelihood-Based Methods for Missing Covariates in the Cox Proportional Hazards Model. *Journal of the American Statistical Association*, **2001**, 96, 292-302	2.8	58
45	Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin₃ lymphoma patients compared with Hodgkin₃ disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). *Leukemia and Lymphoma*, **2001**, 40, 499-509	1.9	32
44	High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. *Journal of Clinical Oncology*, **2001**, 19, 2370-80	2.2	788
43	High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. *Journal of Clinical Oncology*, **2001**, 19, 1430-6	2.2	116
42	Bayesian Survival Analysis. *Springer Series in Statistics*, **2001**,	0.3	530
41	Power prior distributions for regression models. *Statistical Science*, **2000**, 15, 46	2.4	337
40	High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. *Journal of Clinical Oncology*, **2000**, 18, 2444-58	2.2	782
39	Group sequential designs for cure rate models with early stopping in favour of the null hypothesis. *Statistics in Medicine*, **2000**, 19, 3023-35	2.3	7

38	Power prior distributions for generalized linear models. *Journal of Statistical Planning and Inference*, **2000**, 84, 121-137	0.8	48
37	Default Bayes factors for generalized linear models. *Journal of Statistical Planning and Inference*, **2000**, 87, 301-315	0.8	7
36	GEE with Gaussian estimation of the correlations when data are incomplete. *Biometrics*, **2000**, 56, 528-36	1.8	43
35	Bayesian predictive inference for time series count data. *Biometrics*, **2000**, 56, 678-85	1.8	8
34	Longitudinal design for phase I clinical trials using the continual reassessment method. *Contemporary Clinical Trials*, **2000**, 21, 574-88		23
33	The treatment and outcome of cancer patients with thromboses on central venous catheters. *Journal of Thrombosis and Thrombolysis*, **2000**, 10, 271-5	5.1	50
32	On Bayesian inference for proportional hazards models using noninformative priors. *Lifetime Data Analysis*, **2000**, 6, 331-41	1.3	16
31	Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. *Journal of Clinical Oncology*, **2000**, 18, 3782-93	2.2	285
30	Monte Carlo Methods in Bayesian Computation. *Springer Series in Statistics*, **2000**,	0.3	410
29	Dose-intensive therapy for limited-stage small-cell lung cancer: long-term outcome. *Journal of Clinical Oncology*, **1999**, 17, 1175	2.2	45
28	Likelihood methods for incomplete longitudinal binary responses with incomplete categorical covariates. *Biometrics*, **1999**, 55, 214-23	1.8	13
27	Monte Carlo EM for missing covariates in parametric regression models. *Biometrics*, **1999**, 55, 591-6	1.8	80
26	A New Bayesian Model for Survival Data with a Surviving Fraction. *Journal of the American Statistical Association*, **1999**, 94, 909-919	2.8	290
25	Bayesian variable selection for proportional hazards models. *Canadian Journal of Statistics*, **1999**, 27, 701-717	0.4	38
24	Using missing data methods in genetic studies with missing mutation status. *Statistics in Medicine*, **1999**, 18, 473-85	2.3	1
23	Non-ignorable missing covariates in generalized linear models. *Statistics in Medicine*, **1999**, 18, 2435-48	2.3	26
22	A Weighted Estimating Equation for Missing Covariate Data with Properties Similar to Maximum Likelihood. *Journal of the American Statistical Association*, **1999**, 94, 1147-1160	2.8	74
21	A semi-parametric Bayesian approach to generalized linear mixed models. *Statistics in Medicine*, **1998**, 17, 2579-96	2.3	58

20	Bayesian predictive simultaneous variable and transformation selection in the linear model. *Computational Statistics and Data Analysis*, **1998**, 28, 87-103	1.6	6
19	Using Historical Controls to Adjust for Covariates in Trend Tests for Binary Data. *Journal of the American Statistical Association*, **1998**, 93, 1282-1293	2.8	39
18	Estimating Equations with Incomplete Categorical Covariates in the Cox Model. *Biometrics*, **1998**, 54, 1002	1.8	44
17	On Properties of Predictive Priors in Linear Models. *American Statistician*, **1997**, 51, 333-337	5	5
16	The large sample distribution of the weighted log rank statistic under general local alternatives. *Lifetime Data Analysis*, **1997**, 3, 5-12	1.3	34
15	Loss of lung function among sheet metal workers: ten-year study. *American Journal of Industrial Medicine*, **1997**, 32, 460-6	2.7	16
14	A conditional model for incomplete covariates in parametric regression models. *Biometrika*, **1996**, 83, 916-922	2	88
13	Use of Historical Controls in Time-Adjusted Trend Tests for Carcinogenicity. *Biometrics*, **1996**, 52, 1478	1.8	14
12	Parameter Estimation from Incomplete Data in Binomial Regression When the Missing Data Mechanism is Nonignorable. *Biometrics*, **1996**, 52, 1071	1.8	34
11	Using the EM-algorithm for survival data with incomplete categorical covariates. *Lifetime Data Analysis*, **1996**, 2, 5-14	1.3	32
10	A Predictive Approach to the Analysis of Designed Experiments. *Journal of the American Statistical Association*, **1994**, 89, 309-319	2.8	62
9	On Bayesian Analysis of Generalized Linear Models Using Jeffreys Prior. *Journal of the American Statistical Association*, **1991**, 86, 981-986	2.8	90
8	Incomplete Data in Generalized Linear Models. *Journal of the American Statistical Association*, **1990**, 85, 765-769	2.8	200
7	A Power Prior Approach for Leveraging External Longitudinal and Competing Risks Survival Data Within the Joint Modeling Framework. *Statistics in Biosciences*,1	1.5	
6	Incomplete Data in Generalized Linear Models		35
5	On Bayesian Analysis of Generalized Linear Models Using Jeffreys Prior		28
4	A Predictive Approach to the Analysis of Designed Experiments		20
3	A Weighted Estimating Equation for Missing Covariate Data with Properties Similar to Maximum Likelihood		23